このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Sun Pharmaceutical Industries マネジメント
マネジメント 基準チェック /44
現在、CEO に関する十分な情報がありません。
主要情報
Dilip Shanghvi
最高経営責任者
₹60.5m
報酬総額
| CEO給与比率 | 75.6% |
| CEO在任期間 | 31.5yrs |
| CEOの所有権 | 9.6% |
| 経営陣の平均在職期間 | 2.7yrs |
| 取締役会の平均在任期間 | 3.3yrs |
経営陣の近況
Recent updates
Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24
Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Jul 12Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Jun 02CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹104b |
| Mar 31 2024 | ₹61m | ₹46m | ₹96b |
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
| Dec 31 2018 | n/a | n/a | ₹34b |
| Sep 30 2018 | n/a | n/a | ₹24b |
| Jun 30 2018 | n/a | n/a | ₹36b |
| Mar 31 2018 | ₹34m | ₹28m | ₹21b |
報酬と市場: Dilipの 総報酬 ($USD 721.24K ) は、 Indian市場 ($USD 1.21M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Dilipの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Dilip Shanghvi (69 yo)
31.5yrs
在職期間
₹60,541,920
報酬
Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| MD & Chairman of the Board | no data | ₹60.54m | 9.6% ₹ 449.0b | |
| Executive VP | no data | ₹68.75m | 0.12% ₹ 5.6b | |
| Chief Financial Officer | 7.3yrs | ₹38.89m | データなし | |
| Executive Vice-President of Global Operations | no data | データなし | データなし | |
| EVP & Chief Information Officer | less than a year | データなし | データなし | |
| VP, Head of Investor Relations & Strategic Projects | no data | データなし | データなし | |
| Company Secretary & Compliance Officer | 2.7yrs | データなし | データなし | |
| Director of Corporate Development | no data | ₹65.30m | データなし | |
| Chief Human Resources Officer | less than a year | データなし | データなし | |
| Head of India Business | no data | データなし | データなし | |
| Chief Executive Officer of North America Business | 8.1yrs | データなし | データなし | |
| Head of Corporate Relations & CSR - India Regulatory Affairs | no data | データなし | データなし |
2.7yrs
平均在職期間
60yo
平均年齢
経験豊富な経営陣: SUNPHARMAの経営陣は 経験豊富 であると考えられます ( 2.6年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| MD & Chairman of the Board | 31.5yrs | ₹60.54m | 9.6% ₹ 449.0b | |
| Executive VP | 1.3yrs | ₹68.75m | 0.12% ₹ 5.6b | |
| Non-Executive & Non-Independent Director | 30.7yrs | ₹2.20m | 1.8% ₹ 84.1b | |
| Non-Executive & Independent Director | 3.3yrs | ₹5.10m | データなし | |
| Non-Executive Independent Director | 6.3yrs | ₹7.80m | データなし | |
| Independent Director | 1.3yrs | ₹3.20m | データなし | |
| Lead Independent Director | 3.3yrs | ₹8.50m | データなし | |
| Independent Director | 1.8yrs | ₹4.80m | データなし |
3.3yrs
平均在職期間
67.5yo
平均年齢
経験豊富なボード: SUNPHARMAの 取締役会 は 経験豊富 であると考えられます ( 3.3年の平均在任期間)。